Phase 1 Study of the PKMYT1 Inhibitor RP-6306 inCombination With FOLFIRI for the Treatment of AdvancedSolid Tumors (MINOTAUR Study)

Contact:

212-342-5162

NCT Number:

NCT05147350

Protocol:

AAAT9701

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans.

Are you Eligible? (Inclusion Criteria)

  • ≥18 years old
  • have locally advanced or metastatic CRC, GI, or esophageal cancer(s)
  • Life expectancy ≥12 weeks
  • able to swallow oral medications

Specialty Area(s)

Colon and Rectal Cancer, Esophageal Cancer

Principal Investigator

Ryan H. Moy, MD, PhD

Profile Headshot

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps